Page 6 - Raymond Douglas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New treatment discovered for rare eye disease may prevent blindness

Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their

United statesRaymond douglasDrug administrationThyroid eye disease program at cedarsNew england journalThyroid eye disease programWiley chambersOphthalmology productsDrug evaluationBreaking health newsEprotumumab experienced

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting - Viridian Therapeutics (NASDAQ:VRDN) - Press Release

- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation

United statesBarrett katzShoaib ugradarKelly fosterBrent dickinsonYang zhaoRochelle summerfeltJohn jordanDenis oshaughnessyRachel newellRaymond douglasNeither the companySinai medical centerCedars sinai medical centerDevelopment for thyroid eye diseaseStein eye institute

Novel anti-IGF-1R antibody promising treatment for Thyroid Eye Disease in clinical trial

An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm.

Barrett katzRaymond douglasSinai medical centerThyroid eye disease programViridian therapeuticsClinical activity scoreCedars sinai medical centerActivity dataActivity scoreGorman subjective diplopiaChief medical officerVrdn 001Igf 1rThyroid eye diseaseTed patientsEye disease

Viridian reports positive news for patients with Thyroid Eye Disease

Patients with active thyroid eye disease (TED) could benefit from rapid, significant improvements after positive data emerged from a trial.

Raymond douglasSinai medical centerThyroid eye disease programClinical activity scoreCedars sinai medical center

Viridian Therapeutics (VRDN) Reports Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001

Viridian Therapeutics (VRDN) Reports Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBarrett katzContactjohn jordanviridian therapeuticsviceRaymond douglasNeither the companySinai medical centerExchange commissionCompany annual report on formThyroid eye disease programViridian therapeutics incInvestor relations corporate communicationsClinical activity scoreCedars sinai medical centerActivity dataallActivity scoreGorman subjective diplopia